LGND LIGAND PHARMACEUTICALS
2026Q1 · CUSIP 53220K504 · Sector: Healthcare & Biotech
Cooling · Breadth rolling over
Holders
353
Δ holders QoQ
+6
Breadth percentile
Top 39%
Whale holders
163
Δ whales
+1
Inst. holding value
$4.1B
New positions
58
Closed positions
52
Price momentum (1Q)
+10.9%
Put / Call
4/4
Breadth history (34 quarters)
Past Lit Events & Aftermath 8 lit events
| Period | Percentile | Next-1Q return | Next-2Q return |
|---|---|---|---|
| 2025Q4 | Top 15% | +10.9% | — |
| 2025Q3 | Top 6% | -7.5% | +8.1% |
| 2024Q2 | Top 19% | +13.0% | +19.4% |
| 2023Q1 | Top 13% | -15.7% | -28.4% |
| 2022Q3 | Top 18% | -7.5% | -6.7% |
| 2018Q3 | Top 2% | -24.1% | -25.7% |
| 2018Q2 | Top 14% | -38.3% | -50.5% |
| 2018Q1 | Top 6% | +25.4% | -22.7% |
Options Sentiment
Put holders
4
QoQ: +2
Call holders
4
QoQ: 0
See methodology →
Fundamentals
PE (TTM)
39.5
EPS (TTM)
$7.67
EPS YoY
—
Revenue (TTM)
$0.3B
Revenue YoY
+51.2%
Quarterly Revenue & EPS (4Y)
Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable
P/E (TTM) over time
P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden
As of 2026-03-31 · SEC filings (XBRL)